Medicines for rare diseases: Myths and reality

Since 2000, EU regulation has significantly advanced the development of medicines for rare and very rare diseases. According to an analysis by Pharma Fakten, the regulation has enabled private companies to finance the development of such therapies, leading to an unprecedented number of new drugs and research in the field.

Despite these advancements, the sector faces ongoing criticism, particularly regarding allegations of regulatory abuse and profit-seeking by pharmaceutical companies. The analysis aims to debunk common myths associated with the cost and timelines of developing medicines for rare diseases.

A prevalent myth suggests that developing drugs for rare diseases is less burdensome and more cost-effective due to smaller patient populations. However, the report indicates this is not the case. Designing and conducting clinical studies can be substantially more complex and expensive, often requiring significant resources for developing diagnostics and measurement methods.

The claim that medicines for rare diseases develop faster is also challenged. The difficulty in recruiting sufficient patients for global studies, coupled with the complexity and varied manifestations of these diseases, often makes the development process lengthy and arduous. A third myth concerns attempts to underestimate disease prevalence to gain regulatory advantages, but according to the EMA (European Medicines Agency), this is a myth as the agency does not approve such practices.

Pharma Fakten's analysis highlights that while the EU regulation has been successful in promoting drug development, the field of rare disease medicine faces complex challenges that refute simplistic notions about costs and speed.